Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
about
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancerDNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancerHigh BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer.Current controversies in the management of metastatic colorectal cancer.Molecular biomarkers in colorectal carcinoma.Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer.Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients.Current and future biomarkers in colorectal cancer.Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells.Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.Using a constraint-based regression method for relative quantification of somatic mutations in pyrosequencing signals: a case for NRAS analysis.KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients.Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types.Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients.Differences in gene mutations according to gender among patients with colorectal cancer.RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine
P2860
Q33432141-D08F49A3-ED9D-4ADC-9BB5-BD7B1702FF19Q33679684-AA16A28B-CFDC-4231-8717-89557CDEC3F5Q35677169-345DC453-630D-4BA0-8802-58C776760EBBQ35828499-32721F08-2F0F-4DD7-94D3-868E83CF4F6DQ36035723-3ED6C3C7-8187-40A9-89EE-D47132900D38Q36086837-4A7F0BCC-A03B-402C-872F-FF2B94E34AB2Q36115580-83EF2A6B-607C-499F-A26B-D75CD37F3D7AQ36472959-0523A8CB-822F-4412-964C-D548C0F25988Q36629393-1C19857A-C876-498E-A2BB-2D0B5CA6AFEBQ38390840-81FC9697-7845-4201-8FA8-B113356405BAQ38516244-AD6CB5AD-6D9B-45E0-917E-56817F7B5CCDQ38538213-C0B3B31A-02D8-46DB-9649-A90E6AFE2CCAQ38559669-FCEFD62A-8714-409B-8D59-BAC6B772D1D5Q38582586-AC8F04F0-72DA-42F3-9BF9-64AE4F3E855FQ38661498-B47E0580-37F2-4F30-950F-CF5612F8B44DQ39078976-1B31C7B1-9A17-4247-A2C2-038B25D960CFQ39704299-B14BDC6C-F0A9-41F1-B673-FA7ACC8757F4Q40226443-8A8F3B82-8364-4F5A-B110-AEF0682D3E78Q41367522-B2D6F2EF-64A8-4F4D-9478-68BB03C38DEDQ41511712-6F4D50FB-36E9-48D5-99A1-96D73F7533B6Q43492228-761F4128-6527-47D7-986F-2DCA0BDE480FQ46010606-B659B294-CB9A-4E57-AB25-893D53694CB6Q46300809-3847FB31-D6A0-4B3C-985F-83FE173C1847Q47120009-30C6892A-58BD-4EFC-ADE8-3EE7E99A3D2CQ48097655-A19B412A-4817-4B5D-A557-3F5B845256B6Q52582055-62F24B32-AA78-42A8-991C-A75111547038Q53227877-1222AA72-6C75-47FE-8CDA-495742190518Q54260718-6849B6AF-2892-4CBD-8899-F0BC1456E5D6Q55154129-CBA0D854-9DF1-43A0-B836-7BCF87F058F4Q55473473-0A03288E-9CB7-4132-BF14-02787D3D3D50Q57162471-1EF70A17-8A97-48EA-8844-407EF4D4FC54
P2860
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Role of NRAS mutations as prog ...... metastatic colorectal cancer.
@en
Role of NRAS mutations as prog ...... metastatic colorectal cancer.
@nl
type
label
Role of NRAS mutations as prog ...... metastatic colorectal cancer.
@en
Role of NRAS mutations as prog ...... metastatic colorectal cancer.
@nl
prefLabel
Role of NRAS mutations as prog ...... metastatic colorectal cancer.
@en
Role of NRAS mutations as prog ...... metastatic colorectal cancer.
@nl
P2093
P2860
P50
P356
P1476
Role of NRAS mutations as prog ...... n metastatic colorectal cancer
@en
P2093
Carlotta Antoniotti
Cristiana Lupi
Elisa Sensi
Federica Marmorino
Federica Zoratto
Gianluca Masi
Manfredi Morvillo
Veronica De Gregorio
P2860
P356
10.1002/IJC.28955
P50
P577
2014-05-28T00:00:00Z